Suggested remit: To appraise the clinical and cost effectiveness of anitocabtagene autoleucel within its marketing authorisation for treating relapsed or refractory multiple myeloma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Criteria within the (VPAG) met as a new active substance.
2024 voluntary scheme for branded medicines pricing, access and growth - GOV.UK
- Process:
- STA Standard
- ID number:
- 6549
Provisional Schedule
- Committee meeting: 1:
- 07 January 2027
- Expected publication:
- 20 May 2027
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 June 2026 | Invitation to participate |
| 10 June 2026 | In progress. ITP issued |
| 17 March 2026 - 16 April 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6549 |
| 02 October 2025 | Note - Note added to the project documents |
| 04 March 2025 | Topic selection |
| 04 March 2025 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual